Tumor Microenvironment Reshapes Natural Killer Cells Offering New Cancer Therapies

KNOXVILLE, TN, September 09, 2026 /CourierPR/ -- In a groundbreaking review published in *Cancer Biology & Medicine*, researchers from Northwest University and Xijing Hospital, Fourth Military Medical University in China, have revealed the complex behavior of natural killer (NK) cells within tumors. Contrary to previous understanding, the tumor microenvironment actively reshapes NK cells into distinct functional subsets, each with specialized roles. This finding challenges the traditional binary classification of NK cells and paves the way for more precise cancer immunotherapy strategies.

For decades, NK cells were classified into two main groups based on surface markers: one specialized for cytokine production and the other for direct killing. However, this system, derived primarily from blood studies, fails to capture the nuanced behavior of these cells within solid tumors. Inside the tumor microenvironment, factors such as hypoxia, metabolic stress, and immune checkpoint molecules drive NK cells into entirely different functional states.

The study identifies three functionally distinct subsets shaped by the tumor microenvironment: 1. Tumor-Infiltrating Natural Killer (TiNK) Cells: These cells are recruited from blood and often become dysfunctional inside tumors. They downregulate activating receptors such as NKG2D and NKp30, while upregulating inhibitory checkpoints like PD-1, TIGIT, and NKG2A. Their metabolism also falters, with impaired glycolysis and mitochondrial respiration. 2. Tissue-Resident Natural Killer (TrNK) Cells: These cells permanently reside in specific organs and express residency markers such as CD69 and CD103. While their functional plasticity allows them to either suppress tumors or adopt pro-tumorigenic roles, TrNK cells present an intriguing opportunity for therapeutic intervention. 3. Adaptive Natural Killer Cells: The most striking finding is the development of memory-like features in these cells. They can acquire a NKG2C+ phenotype with enhanced antibody-dependent cellular cytotoxicity (ADCC) in response to human cytomegalovirus (HCMV) infection or through cytokine pre-activation with interleukin-12 (IL-12), IL-15, and IL-18, which reprograms them into potent, long-lasting effectors.

The clinical implications of this research are substantial. TiNK cell abundance correlates with prolonged survival in gastric, colorectal, and lung cancers, making it a promising prognostic biomarker. TrNK signatures predict better immunotherapy responses and favorable outcomes across multiple cancer types. Adaptive NK cells, particularly cytokine-induced memory-like natural killer (CIML-NK) cells, have already shown encouraging results in early-phase trials, with a 44% remission rate in patients with acute myeloid leukemia and persistence exceeding three months after infusion.

Emerging strategies include chimeric antigen receptor (CAR)-NK cell engineering, immune checkpoint blockade targeting NKG2A and TIGIT, metabolic modulators such as GPR34 inhibitors, and combination approaches pairing NK cells with cryoablation, radiotherapy, or targeted drugs like sorafenib. The review also highlights next-generation platforms including CRISPR-Cas9 gene editing, induced pluripotent stem cell-derived NK cells, and NK cell-derived extracellular vesicles, all advancing toward clinical translation.

The findings challenge the traditional binary classification of NK cells and offer a new framework for designing more precise cancer immunotherapies. As researchers continue to explore these new subsets, the potential for more effective and personalized cancer treatments grows.